Zoster Brief Pain Inventory
The Zoster BPI is a version of the Brief Pain Inventory (BPI) that is designed specifically for use with patients who have or have had herpes zoster.
In response to the for the pharmaceutical industry on the use of patient-reported outcome measures in medical product development to support labeling claims, we have prepared a BPI User's Guide to provide documentation of the BPI's development and psychometric properties. The information offered therein addresses the recommendations in the FDA guidance and establishes the BPI's adequacy as a measure to support medical product claims.
ZBPI Features
- Purpose: To assess the severity of pain and the impact of pain on daily functioning
- Population: Patients with pain in the region of their rash from herpes zoster
- Assessment areas: Severity of pain, impact of pain on daily function, location of pain, pain medications and amount of pain relief in the past 24 hours or the past week
- Responsiveness: Responds to both behavioral and pharmacological pain interventions
- Method: Self-report or interview
- Time required: Five minutes (short form), 10 minutes (long form)
- Scoring: No scoring algorithm, but "worst pain" or the arithmetic mean of the four severity items can be used as measures of pain severity; the arithmetic mean of the seven interference items can be used as a measure of pain interference
- Reliability: Cronbach alpha reliability ranges from 0.77 to 0.91
ZBPI Language Versions
The BPI is available in the languages shown below. Click on a linked language to view a sample in PDF format.
| Psychometrically and Linguistically Validated | Linguistically Validated |
|---|---|
| English* |
Future Validation Studies: We would like to collaborate with other investigators to develop and validate new language versions of the ZBPI. Contact us at symptomresearch@mdanderson.org for more information. NOTE: The ZBPI may not be modified or translated into another language without the express written consent of the copyright holder (see Notice of Copyright below).
To Order the ZBPI
To use the BPI in a publication or clinical or research trial, you must obtain permission by filling out our and you must comply with the copyright. Fees may apply:
| Type of Use | First Language Version (Per Project) | Additional Language Versions (Per Project) |
|---|---|---|
| Non-funded academic research | No charge | No charge |
| Individual clinical practice | No charge | No charge |
| Funded academic research | $300 | $150 |
| Commercial research | $2,000 | $1,200 |
The ZBPI will be e-mailed to you as a PDF file within 7 to 10 business days. If your request is urgent or the language version you seek is not shown, contact us to make special arrangements:
The Department of Symptom Research
Attn: Assessment Tools
Â鶹ӳ» MD Anderson Cancer Center
1515 Holcombe Boulevard, Unit 1450
Houston, Texas 77030
symptomresearch@mdanderson.org
If applicable, an invoice will be e-mailed to you. Reference the invoice number on your payment and include on the memo line, "MD Anderson Assessment Tool Distribution."
Notice of Copyright
The Brief Pain Inventory (BPI) copyright is held by Dr. Charles S. Cleeland (1991). The copyright applies to the BPI and all its derivatives in any language.
The ZBPI may not be used or reproduced without permission from Charles S. Cleeland, PhD, or his designee. Fees for use may apply (see above).
The BPI may not be modified or translated into another language without the express written consent of the copyright holder. Failure to comply may result in legal action. Contact us via e-mail at symptomresearch@mdanderson.org or at the address shown above to obtain permission to alter or translate the instrument.
Selected References
Validation
Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. J Pain 5(6): 344-356, 2004.
Cleeland CS, Ryan KM. Ann Acad Med Singapore 23(2): 129-138, 1994.
Cleeland CS. Measurement of pain by subjective report. In: Chapman CR, Loeser JD, editors. Advances in Pain Research and Therapy, Volume 12: Issues in Pain Measurement. New York: Raven Press; 1989. pp. 391-403.
Keller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Clin J Pain 20(5): 309-318, 2004.
Clinical Application
Bouhassira D, Chassany O, Gaillat J, Hanslik T, Launay O, Mann C, Rabaud C, Rogeaux O, Strady C. Pain 153(2): 342-349, 2012.
Duracinsky M, Paccalin M, Gavazzi G, El Kebir S, Gaillat J, Strady C, Bouhassira D, Chassany O. BMC Infect Dis 14: 529, 2014.
Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson R. BMC Infect Dis 14: 402, 2014
Laurent B, Vicaut E, Lepl¨¨ge A, Bloch K, Leutenegger E. Med Mal Infect 44(11-12): 515-524, 2014.
Oxman MN, Levin MJ, Johnson GR, et al.; Shingles Prevention Study Group. New Engl J Med 352(22): 2271-2284, 2005.
Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh SS, Levin MJ, Harbecke RM, Oxman MN; Shingles Prevention Study Group. J Am Geriat Soc 58(9): 1634-1641, 2010.
Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan IS, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN. Clin J Pain 23(6): 490-496, 2007.
Serpell M, Gater A, Carroll S, Abetz-Webb L, Mannan A, Johnson R. Health Qual Life Outcomes 12: 92, 2014.
Tyring SK, Stek JE, Smith JG, Xu J, Pagnoni M, Chan IS, Silber JL, Parrino J, Levin MJ. Clin Vaccine Immunol 19(9) 1411-1415, 2012.